Rapport Therapeutics, Inc. (NASDAQ:RAPP) TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 11:20 AM EDT
Company Participants
Abraham Ceesay – CEO, President, Treasurer & Director
Troy Ignelzi – Chief Financial Officer
Conference Call Participants
Joseph Thome – TD Cowen, Research Division
Presentation
Joseph Thome
TD Cowen, Research Division
Hi, everyone, and thank you for joining us at our 2025 Fifth Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. I’m Joe Thome, one of the senior biotech analysts here on the team at TD Cowen. And it’s my pleasure to have with us today the team from Rapport Therapeutics. We have Abe Ceesay, the CEO; and we have Troy Ignelzi, CFO of the company. So thanks, guys, for taking the time.
Question-and-Answer Session
Joseph Thome
TD Cowen, Research Division
Maybe just to kick things off, obviously, impressive Phase II data readout last week that investors were looking for. Maybe at a topline, can you just briefly summarize, I guess, first, how this trial was conducted? And if you want to try and touch on the novel trial design and then maybe hit the high points of the efficacy that you saw and then you can kind of drill down into the details.
Abraham Ceesay
CEO, President, Treasurer & Director
Sure. Happy to, Joe, and I really appreciate the opportunity to be here today and continue to share the story of Rapport, but also share the story on our most recent data.
I think prior to getting into kind of the trial design, just a couple of comments. One, just taking a really big step back. I mean, we are extremely excited about this data, most importantly for patients. This is a very large market, 1.8 million patients in the U.S., defined by the fact that 40% or roughly 560,000 patients continue to be treatment resistant. So
#Rapport #Therapeutics #RAPP #Presents #Cowens #5th #Annual #Mechanisms #Neuropsychiatry #Epilepsy #Summit #Transcript